NanoViricides (NNVC)
XASE:NNVC
Want to see NNVC full AI Analyst Report?
NNVC Stock Chart & Stats
$1.13
-$0.10(-6.54%)
At close: 4:00 PM EST
$1.13
-$0.10(-6.54%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous CloseN/A
Volume409.80K
Average Volume (3M)143.34K
Market Cap
$32.39M
Enterprise Value-$5.15T
Total Cash (Recent Filing)$5.15T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding21,595,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-159.00K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.88M
Enterprise Value/Ebitda667.80K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Nanoviricide PlatformA platform that mimics host-cell binding to neutralize viruses creates a durable R&D advantage: reusable technology across multiple viral indications reduces time and cost to generate new candidates, supports pipeline breadth, and can compound value if clinical proof points emerge.
Very Low Financial LeverageNegligible debt materially lowers solvency risk and interest burden, giving management flexibility to fund clinical programs through equity or grants without immediate refinancing pressure. This structural conservatism supports continuity of R&D through multi‑stage trials.
Orphan Drug Designation For NV-387ODD is a regulatory milestone that can confer development incentives, potential market exclusivity and priority interactions with FDA. These durable benefits improve commercial economics and de-risk regulatory pathways for the targeted indication long term.
Bears Say
No Commercial RevenueAbsent revenue means the business is entirely pre-commercial and dependent on external funding. This limits visibility into product-market fit and sustainable earnings, making long-term viability contingent on successful trials and subsequent commercialization.
Consistent Negative Cash GenerationPersistent operating and free cash outflows indicate ongoing cash burn that must be covered by financing. This structural cash deficit limits runway, increases dilution risk, and forces strategic trade-offs in program advancement if external capital is constrained.
Declining Equity And Dilution RiskA sharp decline in equity reflects cumulative losses and prior dilutive financings. Structurally, this reduces the capital base and implies a high probability of future equity raises, which can dilute existing holders and signal constrained internal funding capacity.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $32.39M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 202 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Overvalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 21,595,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Technical Analysis
Ownership Overview
―
Insiders
3.18% Mutual Funds
0.59% Other Institutional Investors
93.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---